Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial
KEYWORDS: edoxaban, warfarin, stroke, erg, committee, company, people, model, treatment, compared, analysis, fibrillation, atrial fibrillation, noted, atrial

use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final draft guidance. 5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has non-valvular atrial fibrillation and the healthcare professional responsible for their care thinks that edoxaban is the right treatment, it should be available for use, in line with NICE's recommendations.
